De novo mutational signature discovery in tumor genomes using SparseSignatures.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34181655.
- Also identified by DOI 10.1371/journal.pcbi.1009119 and PMC identifier 8270462.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Cancer is the result of mutagenic processes that can be inferred from tumor genomes by analyzing rate spectra of point mutations, or "mutational signatures". Here we present SparseSignatures, a novel framework to extract signatures from somatic point mutation data. Our approach incorporates a user-specified background signature, employs regularization to reduce noise in non-background signatures, uses cross-validation to identify the number of signatures, and is scalable to large datasets. We show that SparseSignatures outperforms current state-of-the-art methods on simulated data using a variety of standard metrics. We then apply SparseSignatures to whole genome sequences of pancreatic and breast tumors, discovering well-differentiated signatures that are linked to known mutagenic mechanisms and are strongly associated with patient clinical features.
Medical subject headings
- DNA Mutational Analysis
- Neoplasms
- Point Mutation